Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.

CStone Pharmaceuticals
基石藥業
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT
ESMO 2025 PREVIEW: CSTONE TO PRESENT PHASE I DOSE-ESCALATION DATA FOR PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY AND TRIAL-IN-PROGRESS UPDATE FOR ROR1 ADC

This announcement is made by CStone Pharmaceuticals (the "**Company**," together with its subsidiaries, collectively referred to as the "**Group**" or "**CStone**") on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

……

The 2025 European Society for Medical Oncology (ESMO) Congress will take place in Berlin, Germany, from October 17 to 21, 2025. Abstracts for CStone's two core clinical assets, clinical data abstract of the ongoing Phase I dose-escalation study for CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) and study design abstract of the ongoing Phase Ib clinical trial for CS5001 (ROR1 Antibody-Drug Conjugate [ADC]), are now available on the official ESMO website.

The CS2009 abstract only contains data from 9 patients as of May 8, 2025 (abstract submission deadline) at the trial's initial stage, meeting ESMO's abstract submission requirements.

CStone will disclose updated preliminary data from the ongoing Phase I dose-escalation clinical study for CS2009 at the upcoming ESMO poster presentation, in approximately 70 advanced solid tumor patients. This will be the world's first clinical data presentation for a PD-1/VEGF/CTLA-4 trispecific antibody.

CS2009 Poster Presentation Schedule:

[Poster Number]: 1545P
[Title]: CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: an open-label, multicenter, phase I first-in-human study
[Presentation Type]: Onsite poster presentation

[Date & Time]: Sunday, October 19, 2025, 12:00-12:45 CEST

CS2009 Data Review Conference Call:

Following the poster presentation, CStone will host an investor meeting to discuss presented data and future clinical development plan. The Company cordially invites all investors to attend this conference call.

Chinese Session:

- **Date & Time**: Monday, October 20, 2025, at 14:00 (Beijing Time)/2:00 (US Eastern Time)
- **Registration Link**: Registration is required, please sign up via the link: https://s.comein.cn/iq2y9krs

English Session:

- **Date & Time**: Monday, October 20, 2025, at 21:00 (Beijing Time)/9:00 (US Eastern Time)
- **Registration Link**: The Zoom meeting link will be sent to you by email after registration via the below link. You may join the meeting by clicking the link in email: https://us06web.zoom.us/webinar/register/WN_PO-SYEhNScyOdlU1p75MdQ

The Phase Ib study design abstract for another core product of the Company - the ROR1-targeting ADC, CS5001 - has been published on the ESMO website and will be presented as an electronic poster (ePoster) during the congress.

CS5001 ePoster Presentation Schedule:

[Poster Number]: 1316eTiP
[Title]: A phase Ib trial of CS5001 (ROR1-ADC) as a single agent and in combination with systemic therapies in patients with advanced solid tumours and lymphomas
[Presentation Type]: ePoster
[Date & Time]: Available online on Saturday, October 18, 2025

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications covering 9 indications. The company's pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: THE COMPANY CANNOT GUARANTEE THAT WE MAY BE ABLE TO ULTIMATELY DEVELOP AND MARKET CS2009 AND CS5001 SUCCESSFULLY. Shareholders of the Company and potential investors are advised to exercise due care when dealing in the shares of the Company.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, October 13, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III and Mr. Edward Hu as non-executive directors, and Mr. Ting Yuk Anthony Wu, Ms. Yip Betty Ho and Mr. Kenneth Howard Jarrett as independent non-executive directors.